Date: 2025/04/02 - 23:32
The FDA's new rule restricting the sale of compounded semaglutide could make it more difficult for some people to obtain affordable weight loss medications. Here, two people who've relied on compounded GLP-1 drugs share their stories.
Date: 2025/04/02 - 23:00
The FDA's new rule restricting the sale of compounded semaglutide could make it more difficult for some people to obtain affordable weight loss medications. Here, two people who've relied on compounded GLP-1 drugs share their stories.
Date: 2025/03/20 - 00:00
The FDA ordered compounding pharmacies to stop making copycat versions of weight loss drugs like Ozempic and Zepbound now that the GLP-1 drug shortage has ended. People who rely on compounded GLP-1s say they may not be able to afford brand-name versions, which are often not covered by insurance.
Date: 2025/03/17 - 15:01
People without diabetes can lose up to 13% of their starting weight in 6 months using tirzepatide (Mounjaro) as an off-label treatment, according to a new study funded by pharmaceutical company Eli Lilly.
Date: 2025/02/10 - 21:00
A new review reports that nine people taking semaglutide and tirzepatide — the active ingredient in GLP-1 medications — experienced vision issues, including three potentially blinding eye conditions.
Date: 2025/01/28 - 15:31
A combination of an SGLT-2 inhibitor drug and a moderately calorie-restrictive diet leads to higher rates of type 2 diabetes remission compared to just calorie restriction alone, new research has found.
Date: 2025/01/22 - 00:32
A large study published in Nature Medicine reviewed the effects of GLP-1 drugs like Ozempic and Mounjaro on 175 different health outcomes. The findings show benefits for brain and heart health, but risks of developing gastrointestinal, kidney, and pancreatic issues.
Date: 2025/01/21 - 20:31
A new study compares the benefits and risks of taking GLP-1 medications for weight loss, including risks of dementia, addiction, heart disease, and gastrointestinal problems, among others.